# US 2003/0229055 A1 · Methods of simultaneously treating ocular rosacea and acne rosacea

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0229055 A1
- Document ID: US20030229055A1
- Status: Published application
- Kind: A1
- Application number: 10/414,808
- Filed: 2003-04-16
- Published: 2003-12-11
- Earliest claimed: 2002-04-16
- Assignees: CollaGenex Pharmaceuticals, Inc.
- Inventors: Robert A. Ashley
- Web page: https://patentgrep.com/patent/US20030229055A1

## CPC

- A61K 31/65: Tetracyclines
- A61P 17/10: Anti-acne agents
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for simultaneously treating ocular rosacea and acne rosacea in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat ocular rosacea and acne rosacea but has substantially no antibiotic activity.

## Claims

### Claim 1

A method for simultaneously treating ocular rosacea and acne rosacea in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat ocular rosacea and acne rosacea but has substantially no antibiotic activity.

### Claim 2 (depends on 1)

A method according to claim 1 further comprising observing a positive result in said simultaneous treatment of said ocular rosacea and acne rosacea.

### Claim 3 (depends on 2)

A method according to claim 2 further comprising continuing treatment.

### Claim 4

A method for simultaneously treating blepharitis and acne rosacea in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat blepharitis and acne rosacea but has substantially no antibiotic activity.

### Claim 5 (depends on 4)

A method according to claim 4 further comprising observing a positive result in said simultaneous treatment of said blepharitis and acne rosacea.

### Claim 6 (depends on 5)

A method according to claim 5 further comprising continuing treatment.

### Claim 7 (depends on 1)

A method according to claim 1, wherein said tetracycline compound is an antibiotic tetracycline compound administered in an amount which is 10-80% of the antibiotic amount.

### Claim 8 (depends on 1)

A method according to claim 1, wherein said tetracycline compound is doxycycline administered twice a day in a dose of 20 mg.

### Claim 9 (depends on 1)

A method according to claim 1, wherein said tetracycline compound is minocycline administered once a day in a dose of 38 mg.

### Claim 10 (depends on 1)

A method according to claim 1, wherein said tetracycline compound is minocycline administered twice a day in a dose of 38 mg.

### Claim 11 (depends on 1)

A method according to claim 1, wherein said tetracycline compound is minocycline administered three times a day in a dose of 38 mg.

### Claim 12 (depends on 1)

A method according to claim 1, wherein said tetracycline compound is minocycline administered four times a day in a dose of 38 mg.

### Claim 13 (depends on 1)

A method according to claim 1, wherein said tetracycline compound is tetracycline administered once a day in a dose of 60 mg/day.

### Claim 14 (depends on 1)

A method according to claim 1, wherein said tetracycline compound is tetracycline administered twice a day in a dose of 60 mg/day.

### Claim 15 (depends on 1)

A method according to claim 1, wherein said tetracycline compound is tetracycline administered three times a day in a dose of 60 mg/day.

### Claim 16 (depends on 1)

A method according to claim 1, wherein said tetracycline compound is tetracycline administered four times a day in a dose of 60 mg/day.

### Claim 17 (depends on 1)

A method according to claim 1, wherein said tetracycline compound is an antibiotic tetracycline compound administered in an amount which results in a serum concentration which is 10-80% of the minimum antibiotic serum concentration.

### Claim 18 (depends on 1)

A method according to claim 1, wherein said tetracycline compound is doxycycline administered in an amount which results in a serum concentration which is 1.0 μg/ml.

### Claim 19 (depends on 1)

A method according to claim 1, wherein said tetracycline compound is minocycline administered in an amount which results in a serum concentration which is 0.8 μg/ml.

### Claim 20 (depends on 1)

A method according to claim 1, wherein said tetracycline compound is tetracycline administered in an amount which results in a serum concentration which is 0.5 μg/ml.

### Claim 21 (depends on 7, 17)

A method according to claim 7 or 17, wherein said antibiotic tetracycline compound is doxycycline, minocycline, tetracycline, oxytetracycline, chlortetracycline, demeclocycline or pharmaceutically acceptable salts thereof.

### Claim 22 (depends on 21)

A method according to claim 21, wherein said antibiotic tetracycline compound is doxycycline.

### Claim 23 (depends on 22)

A method according to claim 22, wherein said doxycycline is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 μg/ml.

### Claim 24 (depends on 22)

A method according to claim 22, wherein said doxycycline is administered in an amount of 20 milligrams once daily.

### Claim 25 (depends on 23)

A method according to claim 23, wherein said doxycycline is administered by sustained release over a 24 hour period.

### Claim 26 (depends on 25)

A method according to claim 25, where said doxcycline is administered in an amount of 40 milligrams.

### Claim 27 (depends on 1)

A method according to claim 1, wherein said tetracycline compound is a non-antibiotic tetracycline compound.

### Claim 28 (depends on 27)

A method according to claim 27, wherein said non-antibiotic tetracycline compound is:
4-de(dimethylamino)tetracycline (CMT-1),
tetracyclinonitrile (CMT-2),
6-demethyl-6-deoxy-4-de(dimethylamino)tetracycline (CMT-3),
4-de(dimethylamino)-7-chlorotetracycline (CMT-4),
tetracycline pyrazole (CMT-5)
4-hydroxy-4-de(dimethylamino)tetracycline (CMT-6),
4-de(dimethylamino)-12α-deoxytetracycline (CMT-7),
6-α-deoxy-5-hydroxy-4-de(dimethylamino)tetracycline (CMT-8),
4-de(dimethylamino)-12α-deoxyanhydrotetracycline (CMT-9), or
4-de(dimethylamino)minocycline (CMT-10).

### Claim 29 (depends on 27)

A method according to claim 27, wherein the non-antibiotic tetracycline compound is selected from the group consisting of:
14
wherein:
R7 is selected from the group consisting of hydrogen, amino, nitro, mono(lower alkyl) amino, halogen, di(lower alkyl)amino, ethoxythiocarbonylthio, azido, acylamino, diazonium, cyano, and hydroxyl;
R6-a is selected from the group consisting of hydrogen and methyl;
R6 and R5 are selected from the group consisting of hydrogen and hydroxyl;
R8 is selected from the group consisting of hydrogen and halogen;
R9 is selected from the group consisting of hydrogen, amino, azido, nitro, acylamino, hydroxy, ethoxythiocarbonylthio, mono(lower alkyl) amino, halogen, diazonium, di(lower alkyl)amino and RCH(NH2)CO;
R is hydrogen or lower alkyl; and
pharmaceutically acceptable salts thereof; with the following provisos:
when either R7 and R9 are hydrogen then R8 must be halogen; and
when R6-a, R6, R5 and R9 are all hydrogen and R7 is hydrogen, amino, nitro, halogen, dimethylamino or diethylamino, then R8 must be halogen; and
when R6-a is methyl, R6 and R9 are both hydrogen, R5 is hydroxyl, and R7 is hydrogen, amino, nitro, halogen or diethylamino, then R8 is halogen; and
when R6-a is methyl, R6 is hydroxyl, R5, R7 and R9 are all hydrogen, then R8 must be halogen; and
when R6-a, R6 and R5 are all hydrogen, R9 is methylamino and R7 is dimethylamino, then R8 must be halogen; and
when R6-a is methyl, R6 is hydrogen, R5 is hydroxyl, R9 is methylamino and R7 is dimethylamino, then R8 must be halogen; and
when R6-a is methyl, R6, R5 and R9 are all hydrogen and R7 is cyano, then R8 must be halogen.

### Claim 30 (depends on 27)

A method according to claim 27, wherein the non-antibiotic tetracycline compound is selected from the group consisting of:
15
wherein:
R7 is selected from the group consisting of hydrogen, amino, nitro, mono(lower alkyl) amino, halogen, and di(lower alkyl)amino, ethoxythiocarbonylthio, azido, acylamino, diazonium, cyano, and hydroxyl;
R6-a is selected from the group consisting of hydrogen and methyl;
R6 and R5 are selected from the group consisting of hydrogen and hydroxyl;
R4 is selected from the group consisting of NOH, N—NH—A, and NH—A,
where A is a lower alkyl group;
R8 is selected from the group consisting of hydrogen and halogen;
R9 is selected from the group consisting of hydrogen, amino, azido, nitro, acylamino, hydroxy, ethoxythiocarbonylthio, mono(lower alkyl) amino, halogen, di(lower alkyl)amino and RCH(NH2)CO;
R is hydrogen or lower alkyl; and
pharmaceutically acceptable salts thereof; with the following provisos:
when R4 is NOH, N—NH-alkyl or NH-alkyl and R7, R6-a, R6, R5, and R9 are all hydrogen, then R8 must be halogen; and
when R4 is NOH, R6-a is methyl, R6 is hydrogen or hydroxyl, R7 is halogen, R5 and R9 are both hydrogen, then R8 must be halogen; and
when R4 is N—NH-alkyl, R6-a is methyl, R6 is hydroxyl and R7, R5, R9 are all hydrogen, then R8 must be halogen; and
when R4 is NH-alkyl, R6-a, R6, R5 and R9 are all hydrogen, R7 is hydrogen, amino, mono(lower alkyl)amino, halogen, di(lower alkyl)amino or hydroxyl, then R8 must be halogen; and
when R4 is NH-alkyl, R6-a is methyl, R6 and R9 are both hydrogen, R5 is hydroxyl, and R7 is mono(lower alkyl)amino or di(lower alkyl)amino, then R8 must be halogen; and
when R4 is NH-alkyl, R6-a is methyl, R6 is hydroxy or hydrogen and R7, R5, and R9 are all be hydrogen, then R8 must be halogen.

### Claim 31 (depends on 27)

A method according to claim 27 wherein the non-antibiotic tetracycline compound is selected from the group consisting of:
16
wherein: R7, R8, and R9 taken together in each case, have the following meanings:
12 R7 R8 R9 azido hydrogen hydrogen dimethylamino hydrogen azido hydrogen hydrogen amino hydrogen hydrogen azido hydrogen hydrogen nitro dimethylamino hydrogen amino acylamino hydrogen hydrogen hydrogen hydrogen acylamino amino hydrogen nitro hydrogen hydrogen (N,N-dimethyl)glycylamino amino hydrogen amino hydrogen hydrogen ethoxythiocarbonylthio dimethylamino hydrogen acylamino dimethylamino hydrogen diazonium dimethylamino chloro amino hydrogen chloro amino amino chloro amino acylamino chloro acylamino amino chloro hydrogen acylamino chloro hydrogen monoalkylamino chloro amino nitro chloro amino dimethylamino chloro acylamino dimethylamino chloro dimethylamino hydrogen hydrogen dimethylamino dimethylamino hydrogen hydrogen trimethylammonium hydrogen hydrogen and 17 Structure L 18 Structure M 19 Structure N 20 Structure O
wherein: R7, R8, and R9 taken together in each case, have the following meanings:
13 R7 R8 R9 azido hydrogen hydrogen dimethylamino hydrogen azido hydrogen hydrogen amino hydrogen hydrogen azido hydrogen hydrogen nitro dimethylamino hydrogen amino acylamino hydrogen hydrogen hydrogen hydrogen acylamino amino hydrogen nitro hydrogen hydrogen (N,N-dimethyl)glycylamino amino hydrogen amino hydrogen hydrogen ethoxythiocarbonylthio dimethylamino hydrogen acylamino hydrogen hydrogen diazonium hydrogen hydrogen dimethylamino diazonium hydrogen hydrogen ethoxythiocarbonylthio hydrogen hydrogen dimethylamino chloro amino amino chloro amino acylamino chloro acylamino hydrogen chloro amino amino chloro hydrogen acylamino chloro hydrogen monoalkylamino chloro amino nitro chloro amino and 21 Structure P
wherein: R8 is hydrogen or halogen and R9 is selected from the group consisting of nitro, (N,N-dimethyl)glycylamino, and ethoxythiocarbonylthio; and
22
wherein: R7, R8, and R9 taken together in each case, have the following meanings:
14 R7 R8 R9 amino hydrogen hydrogen nitro hydrogen hydrogen azido hydrogen hydrogen dimethylamino hydrogen azido hydrogen hydrogen amino hydrogen hydrogen azido hydrogen hydrogen nitro bromo hydrogen hydrogen dimethylamino hydrogen amino acylamino hydrogen hydrogen hydrogen hydrogen acylamino amino hydrogen nitro hydrogen hydrogen (N,N-dimethyl)glycylamino amino hydrogen amino diethylamino hydrogen hydrogen hydrogen hydrogen ethoxythiocarbonylthio dimethylamino hydrogen methylamino dimethylamino hydrogen acylamino dimethylamino chloro amino amino chloro amino acylamino chloro acylamino hydrogen chloro amino amino chloro hydrogen acylamino chloro hydrogen monoalkylamino chloro amino nitro chloro amino
and pharmaceutically acceptable salts thereof.

### Claim 32 (depends on 27)

A method according to claim 27, wherein the non-antibiotic tetracycline compound is selected from the group consisting of:
23 24
wherein:
R7 is selected from the group consisting of hydrogen, amino, nitro, mono(lower alkyl) amino, halogen, di(lower alkyl)amino, ethoxythiocarbonylthio, azido, acylamino, diazonium, cyano, and hydroxyl;
R6-a is selected from the group consisting of hydrogen and methyl;
R6 and R5 are selected from the group consisting of hydrogen and hydroxyl;
R8 is selected from the group consisting of hydrogen and halogen;
R9 is selected from the group consisting of hydrogen, amino, azido, nitro, acylamino, hydroxy, ethoxythiocarbonylthio, mono(lower alkyl) amino, halogen, diazonium, di(lower alkyl)amino and RCH(NH2)CO;
R is hydrogen or lower alkyl;
Ra and Rb are selected from the group consisting of hydrogen, methyl, ethyl, n-propyl and 1-methylethyl with the proviso that Ra and Rb cannot both be hydrogen;
Rc and Rd are, independently, (CH2)nCHRe wherein n is 0 or 1 and Re is selected from the group consisting of hydrogen, alkyl, hydroxy, lower(C1-C3) alkoxy, amino, or nitro; and,
W is selected from the group consisting of (CHRe)m wherein m is 0-3 and said Re is selected from the group consisting of hydrogen, alkyl, hydroxy, lower(C1-C3) alkoxy, amino, nitro, NH, N(C1-C3) straight chained or branched alkyl, O, S and N(C1-C4) straight chain or branched alkoxy; and,
pharmaceutically acceptable salts thereof.

### Claim 33 (depends on 32)

A method according to claim 32, wherein the non-antibiotic tetracycline compound selected from the group consisting of structures S-Z has the following provisos:
when either R7 and R9 are hydrogen then R8 must be halogen; and
when R6-a, R6, R5 and R9 are all hydrogen and R7 is hydrogen, amino, nitro, halogen, dimethylamino or diethylamino, then R8 must be halogen; and
when R6-a is methyl, R6 and R9 are both hydrogen, R5 is hydroxyl, and R7 is hydrogen, amino, nitro, halogen or diethylamino, then R8 is halogen; and
when R6-a is methyl, R6 is hydroxyl, R5, R7 and R9 are all hydrogen, then R8 must be halogen; and
when R6-a, R6 and R5 are all hydrogen, R9 is methylamino and R7 is dimethylamino, then R8 must be halogen; and
when R6-a is methyl, R6 is hydrogen, R5 is hydroxyl, R9 is methylamino and R7 is dimethylamino, then R8 must be halogen; and
when R6-a is methyl, R6, R5 and R9 are all hydrogen and R7 is cyano, then R8 must be halogen.

### Claim 34 (depends on 1)

A method according to claim 1, wherein said tetracycline compound has a photoirritancy factor of less than the photoirritancy factor of doxycycline.

### Claim 35 (depends on 1)

A method according to claim 1, wherein said tetracycline compound has a photoirritancy factor from about one to about two.

### Claim 36 (depends on 35)

A method according to claim 35, wherein said tetracycline compound has a general formula:
25
wherein R7, R8, and R9 taken together are, respectively, hydrogen, hydrogen and dimethylamino.

### Claim 37 (depends on 1)

A method according to claim 1, wherein said tetracycline compound has a photoirritancy factor from about 1.0 to about 1.2.

### Claim 38 (depends on 37)

A method according to claim 37, wherein said tetracycline compound is selected from the group consisting of:
26
wherein R7, R8, and R9 taken together in each case, have the following meanings:
15 R7 R8 R9 hydrogen hydrogen amino hydrogen hydrogen palmitamide and 27 Structure L 28 Structure M 29 Structure N 30 Structure O
wherein R7, R8, and R9 taken together in each case, have the following meanings:
16 R7 R8 R9 hydrogen hydrogen acetamido hydrogen hydrogen dimethylaminoacetamido hydrogen hydrogen nitro hydrogen hydrogen amino and 31 Structure P
wherein R8, and R9 taken together are, respectively, hydrogen and nitro.

### Claim 39 (depends on 1)

A method according to claim 1, wherein said systemic administration is oral administration, intravenous injection, intramuscular injection, subcutaneous administration, transdermal administration or intranasal administration.

### Claim 40

A method for simultaneously treating ocular rosacea and acne rosacea in a human in need thereof comprising administering topically to said human a non-antibiotic tetracycline compound in an amount that is effective to treat ocular rosacea and acne rosacea.

### Claim 41 (depends on 40)

A method according to claim 40 further comprising observing a positive result in said simultaneous treatment of said ocular rosacea and acne rosacea.

### Claim 42 (depends on 41)

A method according to claim 41 further comprising continuing treatment.

### Claim 43

A method for simultaneously treating blepharitis and acne rosacea in a human in need thereof comprising administering topically to said human a non-antibiotic tetracycline compound in an amount that is effective to treat blepharitis and acne rosacea.

### Claim 44 (depends on 43)

A method according to claim 43 further comprising observing a positive result in said simultaneous treatment of said blepharitis and acne rosacea.

### Claim 45 (depends on 43)

A method according to claim 43 further comprising continuing treatment.
